Millennium Management
CRSP icon

Millennium Management’s CRISPR Therapeutics CRSP Stock Holding History

Millennium Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,400
Closed -$389K – 6846
2021
Q2 		$389K Sell
2,400
-5,100
-68% -$620K ﹤0.01% 5504
2021
Q1 		$914K Buy
+7,500
New +$1.13M ﹤0.01% 4304

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management's CRSP Position: Q1 2026 in Review

Millennium Management increased its CRISPR Therapeutics (CRSP) stake by 1,137% in Q1 2026, buying an estimated $18.3M and bringing the position to 377,178 shares worth $17.9M. The position accounts for 0.01% of the portfolio, ranked #1644.

Millennium Management first reported a position in CRSP in Q4 2016 and has held it in 29 quarters since. The position peaked at $29.2M in Q4 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Millennium Management held 377,178 shares of CRISPR Therapeutics worth $17.9M as of Q1 2026.
  • Millennium Management bought 346,686 CRISPR Therapeutics shares in Q1 2026, an estimated $18.3M.
  • CRISPR Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1644 holding.
  • Millennium Management first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 29 quarters since.
  • Millennium Management's CRISPR Therapeutics position peaked at $29.2M in Q4 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.